1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 5 to 40 at diagnostic biopsy
Sponsor: NCI
Protocol IDs: COG-AOST0331, AOST0331, NCT00134030, ISRCTN67613327, EU-20530, MRC-EURAMOS1, MRC-BO08, EUDRACT-2004-000242-20
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 5 to 50
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: FRE-FNCLCC-SARCOME-09-0603, FRE-FNCLCC-OS-2006, NOVARTIS-FRE-FNCLCC-SARCOME-09-0603, CHUGAI-FRE-FNCLCC-SARCOME-09-0603, EU-20729, EUDRACT-2006-00337727, SARCOME 09/0603, NCT00470223
|
|
3.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 1 to 18
Sponsor: NCI
Protocol IDs: COG-ACCL0431, ACCL0431, NCT00716976
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: OS2008, NCT00667342
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AP23573-07-302, NCT00538239
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 50
Sponsor: Pharmaceutical / Industry
Protocol IDs: TR02-2421, NCT00102531
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 10 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A4021020, NCT00560235
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 8 to 65
Sponsor: Other
Protocol IDs: 381, NCT00689195
|
|
9.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 25
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07053, 07053, CA180 121, NCT00788125
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 6 to 120
Sponsor: Other
Protocol IDs: HITHD-01, NCT01005043
|
|
11.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: MSKCC-05122, NCT00445965
|
|
12.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: CINJ-3330, NCT00161187
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 13
Sponsor: Other
Protocol IDs: SARC009, NCT00464620
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 18
Sponsor: NCI
Protocol IDs: NCI-07-C-0230, 07-C-0230, NCT00550654
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: NCI, Other
Protocol IDs: 05-326, NCT00592293
|
|
16.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UMCC 2008.049, NCT00743509
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 74
Sponsor: Other
Protocol IDs: SARC012, D8180C00039, NCT00752206
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001C24114, EUDRACT- Nr. 2007-005294-60, NCT00767819
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-1299, NCT00802880
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 to 70
Sponsor: Other
Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 15 to 75
Sponsor: Other
Protocol IDs: HGosteo-BAY, EudraCT Number: 2007-004396-19, NCT00889057
|
|
22.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CCCWFU-71108, CCCWFU 71108, IRB00008212, NCT00974545
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-09097, 09-097, 8121, NCT01016015
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 13 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2009_688, MK8669-030, NCT01010672
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-00-C-0121, NCI-41, 41, NCT00020163
|
